Navigation Links
Study affirms effectiveness of medication for juvenile rheumatoid arthritis
Date:5/8/2008

Juvenile rheumatoid arthritis (JRA) is a chronic autoimmune disease that strikes children between the ages of newborn to 16 years. All children with JRA have joint pain, stiffness, and swelling and some also have fever and skin rashes. JRA can impede growth, damage joints, and lead to disability in adulthood. Traditionally, children with JRA have been treated with the same drugs prescribed to adults with inflammatory diseases: corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and disease-modifying antirheumatic drugs (DMARDs) such as methotrexate (MTX). Unfortunately, these medications fail to improve disease activity for many children with JRA.

Tumor necrosis factor (TNF) plays a key role in the inflammatory process. In the past decade, TNF-blockers have brought dramatic gains in treatment for rheumatoid arthritis patients. Etanercept, the only FDA-approved biologic for JRA patients until very recently, has also been proven highly effective and safe for children in short-term trials. Yet, since many children with JRA have active disease that lasts for many years, past adolescence and into adult life for many, assurance of the effectiveness and safety of long-term anti-TNF treatment is essential.

Toward that goal, the Pediatric Rheumatology Collaborative Study Groupcomprised of over 70 pediatric rheumatology centers in the US and Canada has been conducting a trial of etanercept in JRA patients for more than 8 years. The group shares reassuring news for pediatricians, parents, and, above all, children afflicted with JRA in the May 2008 issue of Arthritis & Rheumatism (www.interscience.wiley.com/journal/arthritis).

To evaluate the long-term therapeutic value of etanercept, the study group began with a randomized controlled trial, focusing on 69 JRA patients between the ages of 4 and 17 years. Treatment with MTX and other DMARDs was discontinued a minimu
'/>"/>

Contact: Sean Wagner
swagner@wiley.com
781-388-8550
Wiley-Blackwell
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Study identifies molecular response of cartilage to injury
2. Skin flaps deliver cancer-fighting therapy, ASPS study reveals
3. Pilot Study to Assess Safety and Efficacy of Medidur(TM) FA in AMD Patients Treated With Lucentis(R)
4. MIT study suggests caution on new anti-obesity drug in kids
5. Preliminary Results from Phase 2 Genzyme Study Highlight Potential of Novel Oral Compound for Gaucher Disease
6. Study in mice suggests molecules in plants have beneficial effect on Alzheimers disease
7. Women and heart attack: Study finds failure to recognize symptoms, failure to treat appropriately
8. Weill Cornell receives funding to study creation of new elder abuse center
9. Pilot study reinforces use of portable anteroom HEPA filtration
10. Warning: New Skin Cancer Study Finds Outdoor Workers are Less Likely to Get Screened for Skin Cancer
11. Study shows physician judgement important in reducing RSV-related hospitalizations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... October 01, 2014 Familylifeinsurancequotes.org has ... life insurance for senior citizens. , Senior citizens ... will now sell coverage to seniors who are over ... be purchased without taking a medical examination. , Term ... online and senior clients can qualify. Having life insurance ...
(Date:10/1/2014)... 01, 2014 Insuranceragents.info has released ... good life insurance plan for vulnerable family members. , ... family members. Providers in the family should always carry ... financial hardships for the rest of the family. ... Families can benefit more from temporary coverage or from ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog post explaining how ... , Smoking will always have a negative impact on ... method to find affordable coverage. Insurance brokerage websites specialize ... , Whole life insurance premiums will be fixed throughout ... is permanent, the initial rates are very important. ...
(Date:10/1/2014)... Phoseon Technology, the pioneer in developing ... business worldwide. This rapid growth includes increased hiring for ... efforts. The company has experienced average annual growth rates ... this growth to continue in the future as new ... , “We are very pleased that UV ...
(Date:10/1/2014)... Conn. (PRWEB) October 01, 2014 ... company, including a redefined mission and visual identity ... power of partnering with them to create greater ... agile brand that focuses on empowering customers to ... communications. , The crown jewel of the rebrand ...
Breaking Medicine News(10 mins):Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Farmington Company Launches Rebrand and New Positioning 2
... to thwart tumor,s comeback , , WEDNESDAY, Jan. 21 ... cancer stem cells or "tumor-initiating cells" which, when targeted ... malignant. , The finding bolsters the theory that cancer ... are resistant to conventional therapies and responsible for tumor ...
... January 2009 - A new study conducted at the ... the University of Bologna, and published by Elsevier in ... http://www.elsevier.com/locate/cortex ) shows that, in confabulating patients, memory accuracy ... cognitive processes supporting adaptive behavior need attentional resources for ...
... Technical University of Catalonia (UPC) and Universitat Autnoma de ... (ESA) to design and carry out a scientific experiment ... between drugs and cells differ under these conditions. The ... Vaquer, with a doctorate in Medicine from UAB, and ...
... Erdman, A Cogdell,Spencer Company, a subsidiary of Cogdell ... broke ground earlier this week on two new medical ... , The two projects, a ... Jackson, Tennessee and a $1.75 million cancer center in,Mebane, ...
... 21 Amil,Participacoes S.A. (Bovespa: AMIL3) ("Amilpar"), informs its ... a meeting held today, approved the,payment of Interest on ... per,common share, corresponding to the total amount of R$ ... 2009, based on shareholders, position of,January 21, 2009. , ...
... & Friends Stage Show Kicks-off This Month Helping ... Raise Funds for Research. Autism Speaks, the ... yearlong partnership with Thomas & FriendsTM Live! On ... musical stage show produced by AEG ThemeSTAR and ...
Cached Medicine News:Health News:Targeting Cancer's Own Stem Cells to Fight Recurrence 2Health News:Targeting Cancer's Own Stem Cells to Fight Recurrence 3Health News:When less attention improves behavior 2Health News:Students from UAB and UPC will experiment under microgravity conditions at the ESA 2Health News:Students from UAB and UPC will experiment under microgravity conditions at the ESA 3Health News:Cogdell Spencer Breaks Ground on Projects in Tennessee and North Carolina 2Health News:Cogdell Spencer Breaks Ground on Projects in Tennessee and North Carolina 3Health News:Amilpar - Notice to Shareholders - Distribution of Interest on Capital Stock 2Health News:Autism Speaks Announces Yearlong Partnership With Thomas & Friends (TM) Live! On Stage: A Circus Comes To Town 2Health News:Autism Speaks Announces Yearlong Partnership With Thomas & Friends (TM) Live! On Stage: A Circus Comes To Town 3Health News:Autism Speaks Announces Yearlong Partnership With Thomas & Friends (TM) Live! On Stage: A Circus Comes To Town 4Health News:Autism Speaks Announces Yearlong Partnership With Thomas & Friends (TM) Live! On Stage: A Circus Comes To Town 5
(Date:9/30/2014)... Aileron Therapeutics, Inc. - Product Pipeline ... Direct,s, ,Aileron Therapeutics, Inc. - Product Pipeline Review ... Therapeutics, Inc.,s pharmaceutical research and development focus. ... therapeutic developmental pipeline of Aileron Therapeutics, Inc.,s, complete ... by drug target, mechanism of action (MoA), route ...
(Date:9/30/2014)... DALLAS , September 30, 2014 /PRNewswire/ ... market research report the "Glycobiology/Glycomics Market by Product ... Spectrometry, MALDI-TOF), Kits, and Reagents], Application (Immunology, ... Forecast to 2019", published by MarketsandMarkets, provides ... restraints, challenges, opportunities, current market trends, and ...
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 ... stage. Growing ageing population and rise in the incidence ... of chronic wounds and in affordability of better quality ... Chinese wound care market. Universal coverage of public health ... products would further stimulate demand. Based on the findings ...
Breaking Medicine Technology:Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4China Wound Care Market 2China Wound Care Market 3
... Chamber Lenses: The Bausch & Lomb PMMA Posterior ... for primary implantation for the visual correction of ... older where a cataractous lens has been removed ... to be placed in the ciliary sulcus or ...
... are manufactured using the highest ... CQ UV PMMA material is ... single piece lenses. Unioptic lens ... nonphaco and phaco styles. All ...
... STAARVISC II is a sterile nonpyrogenic, ... hyaluronate. STAARVISC II contains 12 mg/ml of ... daltons) sodium hyaluronate dissolved in physiological saline. ... the viscosity is 105,000 cps (105 Pa ...
... viscoelastic agent for the surgeon who performs ... Amvisc possesses sufficient viscosity for excellent chamber ... cohesive so that complete removal at the ... quickly accomplished. Amvisc is priced to compete ...
Medicine Products: